Immunocore downgraded to Neutral from Buy at Guggenheim
PremiumThe FlyImmunocore downgraded to Neutral from Buy at Guggenheim
1M ago
Immunocore downgraded at Guggenheim with trajectory for Kimmtrak appreciated
Premium
The Fly
Immunocore downgraded at Guggenheim with trajectory for Kimmtrak appreciated
1M ago
Immunocore presents Phase 1 data of brenetafusp in ovarian cancer
Premium
The Fly
Immunocore presents Phase 1 data of brenetafusp in ovarian cancer
2M ago
Immunocore reports Q2 EPS (23c), consensus (48c)
PremiumThe FlyImmunocore reports Q2 EPS (23c), consensus (48c)
3M ago
Immunocore announces randomization of first patient in Phase 3 brenetafusp trial
Premium
The Fly
Immunocore announces randomization of first patient in Phase 3 brenetafusp trial
5M ago
Immunocore presents KIMMTRAK clinical data at ASCO 2024
Premium
The Fly
Immunocore presents KIMMTRAK clinical data at ASCO 2024
5M ago
Immunocore price target lowered to $88 from $90 at Mizuho
PremiumThe FlyImmunocore price target lowered to $88 from $90 at Mizuho
6M ago
Immunocore price target raised to $100 from $90 at H.C. Wainwright
Premium
The Fly
Immunocore price target raised to $100 from $90 at H.C. Wainwright
6M ago
Immunocore price target raised to $67 from $63 at Canaccord
Premium
The Fly
Immunocore price target raised to $67 from $63 at Canaccord
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100